Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its 2022 Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Québec. The detailed results of the votes received by proxy are as follows:
Election of Directors
|
Director Nominees
|
|
NUMBER OF SHARES
|
|
PERCENTAGE OF VOTES CAST
|
|
FOR
|
|
WITHHELD
|
|
FOR
|
|
WITHHELD
|
|
Daniel N. Chicoine
|
|
4,616,653
|
|
148,815
|
|
96.9%
|
|
3.1%
|
|
David A. Copeland
|
|
4,378,536
|
|
386,932
|
|
91.9%
|
|
8.1%
|
|
Anthony E. Dobranowski
|
|
4,363,268
|
|
402,200
|
|
91.6%
|
|
8.4%
|
|
John C. London
|
|
4,375,612
|
|
389,856
|
|
91.8%
|
|
8.2%
|
|
Thomas Schlader
|
|
4,692,345
|
|
73,123
|
|
98.5%
|
|
1.5%
|
|
Deborah Shannon-Trudeau
|
|
4,705,132
|
|
60,336
|
|
98.7%
|
|
1.3%
|
Appointment of External Auditors
|
Outcome
|
|
NUMBER OF SHARES
|
|
PERCENTAGE OF VOTES CAST
|
|
FOR
|
|
WITHHELD
|
|
FOR
|
|
WITHHELD
|
|
Ernst & Young LLP reappointed
|
|
5,442,357
|
|
15,130
|
|
99.7%
|
|
0.3%
|
Approval of the Continuation of Crescita’s Shareholder Rights Plan
|
Outcome
|
|
NUMBER OF SHARES
|
|
PERCENTAGE OF VOTES CAST
|
|
FOR
|
|
AGAINST
|
|
FOR
|
|
AGAINST
|
|
Shareholder Rights Plan approved
|
|
4,648,487
|
|
116,981
|
|
97.5%
|
|
2.5%
|
About Crescita Therapeutics Inc.
Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and early to commercial stage prescription products. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For further details, visit www.crescitatherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220512006074/en/